Three new directors elected to Scoular’s Board of DirectorsOmaha, Nebraska, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Scoular shareholders on Tuesday elected three new members to the company’s Board of Directors. They are Diane Duren, a retired Union Pacific executive and Omaha community leader; Stephanie Harlan, entrepreneur, business consultant and daughter of former Scoular CEO Neal Harlan; and Tom Werner, the former CEO of Lamb Weston.
Urban Decay Turns Canter’s Deli Into a One-Night-Only Underground Rave for Its Dirty 30Surprise DJs Tara Yummy and MAAD joined Urban Decay’s past and present community as the brand raided its vault to resurrect Pocket Rocket for one night only
First Hawaiian to Report Third Quarter 2026 Financial Results on October 23, 2026HONOLULU, Oct. 02, 2026 (GLOBE NEWSWIRE) -- First Hawaiian, Inc. (
NASDAQ: FHB) announced today that it plans to release its third quarter 2026 financial results on Friday, October 23, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time).
iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026Following completion of the forensic investigation, company begins notifying impacted individuals
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 90,775 restricted stock units (“RSUs”) and 32,725 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. The foregoing inducement awards were granted as inducements material to the new employees entering into employment with Imagene in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the Company’s 2025 Equity Inducement Plan and the applicable equity award agreements.
National Healthcare Properties Announces Conversion of Class A Common Stock into Common StockNEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (Nasdaq: NHP) (the “Company”) announced today that, as previously disclosed, all outstanding shares of its Class A common stock, $0.01 par value per share (“Class A common stock”), will automatically convert into its common stock, $0.01 par value per share (“common stock”), on a one-for-one basis. All shares of common stock will begin trading on the Nasdaq Global Market, effective at 9:30 a.m. Eastern time on October 19, 2026. The conversion will have no effect on the economic rights of holders of shares of Class A common stock and the Company’s operations.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
pMD® Completes Annual SOC 2® Type II and HIPAA Security AuditsSAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- pMD®, a leading healthcare technology company, today announced it has successfully completed its annual SOC 2® Type II and HIPAA security audits, reaffirming its ongoing investment in protecting sensitive patient data.
Pasqal Appoints Roger L. Chuchen as Head of Investor RelationsExperienced technology and capital markets executive joins Pasqal to lead investor engagement and strengthen the company's public-market presence following its Nasdaq listing
WISeQey’s Subsidiary WISeSat.Space, a Space Technology Company, Completes Business Combination with Columbus Acquisition CorporationWISeQey’s Subsidiary WISeSat.Space, a Space Technology Company, Completes Business Combination with Columbus Acquisition Corporation
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on October 1, 2026, the compensation committee of Apnimed’s board of directors granted 19 new non-executive employees non-qualified stock options to purchase an aggregate of 481,300 shares of the Company’s common stock under Apnimed’s 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $22.54, which is equal to Apnimed’s closing trading price on the grant date. One-fourth of the shares underlying each of the employee’s stock options will vest on the first anniversary of each employee’s start date and in equal monthly installments thereafter for the next three years, subject to such employee’s continued employment with the Company on such vesting dates.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 16,700 shares of Class A common stock and restricted stock units (RSUs) underlying 8,350 shares of Class A common stock to five (5) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on October 1, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 60,000 shares of common stock.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on October 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,478 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation SystemDevelopers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissions
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of the Company’s common stock to two newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of September 30, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units (“RSUs”) to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material inducement to his employment.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of October 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to five newly hired non-executive employees as a material inducement to commencing their employment with the Company.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 71,800 of NewAmsterdam’s ordinary shares to 7 non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
gFiber announces extra speed for 2 Gig customers at no extra costMOUNTAIN VIEW, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- You might have noticed gFiber is sporting a fresh new look—complete with an updated logo and vibrant colors! But while our appearance may be different, our foundational promise remains the same: clear pricing, incredible service, and uncompromising reliability. We’re working to build an internet service you can truly love, which means constantly upgrading our network to deliver faster speeds and richer experiences as the internet continues to develop. It also means taking care of our customers, and making sure the people who’ve been with us for a long time get the same incredible experience as those who just signed up.
Texas Precious Metals Launches Josie Conner 1 oz Silver RoundNew release celebrates one of breakaway roping’s top athletes following her Governor’s Cup victory
JMU launches two-sided guarantee for its graduates and the employers who hire themBeginning with the Class of 2027, JMU’s Employment and Employer Guarantees extend the university’s commitment to career outcomes and continued professional development beyond graduation
Bayer to Invest $2.2 Billion in a New Manufacturing Site in OhioNew Albany, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Ohio Governor Mike DeWine joined Bayer and JobsOhio today to announce Bayer’s plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio.
Gray Sets Date for Third Quarter Earnings Release and Earnings Conference CallATLANTA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Gray Media, Inc. (
NYSE: GTN) today announced that it will release its earnings results for the quarter ending September 30, 2026, on Friday, November 6, 2026.
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5thIf you purchased or acquired Replimune securities between October 20, 2025 and April 10, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff RoleIf you purchased or acquired ARS securities between March 9, 2026, and June 24, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
BASports.com’s Perfect 10-0 NCAA College Football Winning Run Highlights 48-Year Winning LegacyWAUCHULA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- While early-season college football leaves most sports bettors and professional handicappers guessing, BASports.com is once again demonstrating why it stands as the undisputed sports handicapping GOAT. In a major Las Vegas football handicapping contest, BASports.com has surged with an astonishing 10 straight NCAA College Football wins (10-0, 100%, +$10,000 profit), setting a standard that no other service in the country can match.
CFP Board Promotes Public Trust With 19 ActionsUpholding Ethical Standards in a Thriving Network of Over 110,000 CFP® Professionals
ESI Earns First-Ever Place on ENR’s Top 250 Global Contractors ListBOISE, Idaho, Oct. 02, 2026 (GLOBE NEWSWIRE) -- For the first time in its history, Engineered Structures Inc. (ESI) has earned a place on Engineering News-Record's Top 250 Global Contractors list, ranking No. 222 among the world's largest construction contractors.
DATAVAULT URGENT INVESTOR DEADLINE ALERT: Datavault AI Inc. Investors Have Until October 5th to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff RoleBragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In Datavault AI (DVLT) To Contact Them Directly To Discuss Their Options
ALARUM DEADLINE OCTOBER 5th: Bragar Eagel & Squire, P.C. Urges Alarum Technologies Ltd Investors to Contact the Firm Before October 5th Class Action Lead Plaintiff DeadlineIf you purchased or Alarum securities between March 20, 2025 and July 2, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
QCI Introduces AI-Powered Revenue Forecasting for Casino ResortsForecasting and revenue management capabilities connect financial planning with the operational decisions that shape resort performance
Henley & Partners - Argentina Announces New Citizenship by Investment ProgramNew framework adds a significant dimension to Latin America’s evolving wealth mobility landscape as Argentina seeks to attract international capital, entrepreneurs and talent
BLAIZE HOLDINGS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds Blaize Holdings, Inc. Investors to Contact the Firm Regarding Their Rights Before October 5thBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Blaize (BZAI) To Contact Him Directly To Discuss Their Options
Chaince Securities, LLC to Serve as Exclusive Sales Agent for Magic Empire Global Limited’s (NASDAQ: MEGL) US$100 Million At-the-Market Offering ProgramNew York, NY, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Chaince Securities, LLC (“Chaince”), a FINRA-registered broker-dealer and wholly owned subsidiary of Chaince Digital Holdings Inc. (
NASDAQ: CD), today announced that it has been engaged as the exclusive sales agent for the at-the-market (“ATM”) equity offering program of Magic Empire Global Limited (
NASDAQ: MEGL) (the “Company”), a British Virgin Islands-incorporated holding company whose operations are conducted in Hong Kong through its operating subsidiaries and which is principally engaged in corporate finance advisory services. The engagement is made pursuant to an At-the-Market Offering Agreement dated September 30, 2026 (the “Sales Agreement”), under which the Company may offer and sell, from time to time, Class A ordinary shares of the Company (the “Shares”) having an aggregate offering price of up to US$100 million through Chaince, as sales agent.
DAVA Investors Have Opportunity to Lead Endava plc Securities Fraud Lawsuit with SBS LawLOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Endava plc (“Endava” or “the Company”) (
NYSE: DAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Kaplan Fox Notifies AppLovin Corporation (NASDAQ: APP) Investors of a Securities Class Action Deadline on November 16, 2026NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AppLovin Corporation (“AppLovin” or the “Company”) (
NASDAQ: APP) on behalf of investors that purchased or otherwise acquired AppLovin securities between February 12, 2026 and August 5, 2026 (the “Class Period”).
HII Promotes Greg Ennis to Chief Financial Officer of Mission TechnologiesMCLEAN, Va., Oct. 02, 2026 (GLOBE NEWSWIRE) -- HII (
NYSE: HII) announced today that Greg Ennis has been promoted to senior vice president and chief financial officer of its Mission Technologies division. In this role, Ennis will lead the division's financial organization and oversee accounting, financial reporting, financial planning and analysis, rates and budgets, and program cost control across the business.
National Mural Series Highlights Suffrage Leaders in NYC and PortlandPublic art initiative features a national display of the prominent suffrage trailblazers across our country.
Bonduelle - 2025-2026 Annual results: The Bonduelle Group demonstrates its resilience, ending fiscal year 2025-2026 with stable sales and profitabilityBONDUELLEPartnership limited by shares with a capital of 57 102 699,50 eurosHead office : La Woestyne – 59173 Renescure - France447 250 044 RCS Dunkerque
DP World Wins LatinFinance Port Financing of the Year Award in BrazilRecognition honors DP World’s first debenture issuance and its role in financing long-term infrastructure development in Brazil
Mr. Eric Krafft Reports Participation on the Private Placement of Leading Edge Materials Corp.NOT FOR DISTRIBUTION TO UNITED STATES NEWWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLEOR IN PART, IN OR INTO THE UNITED STATES
CARIBBEAN AIRLINES ENHANCES NETWORK OPERATIONS WITH SERVICES TO TORONTO, CARACAS AND PANAMAThe additional services will offer customers greater choice for leisure, business and family travel...
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. (“Doximity” or “the Company”) (
NYSE: DOCS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (
NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
APP Investors Have Opportunity to Lead AppLovin Corporation Securities Fraud Lawsuit with SBS LawLOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AppLovin Corporation (“AppLovin” or “the Company”) (
NASDAQ: APP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
FLNC Investors Have Opportunity to Lead Fluence Energy, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fluence Energy, Inc. (“Fluence” or “the Company”) (
NASDAQ: FLNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
